These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20818913)

  • 1. Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.
    Hanley PJ; Cruz CR; Shpall EJ; Bollard CM
    Cytotherapy; 2010 Oct; 12(6):713-20. PubMed ID: 20818913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications.
    Baron F; Ruggeri A; Nagler A
    Expert Rev Hematol; 2016 Mar; 9(3):297-314. PubMed ID: 26635058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid reconstitution of regulatory T-cell subsets is associated with reduced rates of acute graft-versus-host disease and absence of viremia after cord blood transplantation in children with reduced-intensity conditioning using alemtuzumab.
    Chen X; Hill M; Vander Lugt M; Escolar M; Fang Z; Chen W; Szabolcs P
    Cytotherapy; 2020 Mar; 22(3):149-157. PubMed ID: 32089448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.
    Kim YJ; Broxmeyer HE
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):112-26. PubMed ID: 20727784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-specific T-lymphocyte function after cord blood transplantation.
    Cohen G; Carter SL; Weinberg KI; Masinsin B; Guinan E; Kurtzberg J; Wagner JE; Kernan NA; Parkman R
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1335-42. PubMed ID: 17162216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit.
    Tanaka J; Sugita J; Kato N; Toubai T; Ibata M; Shono Y; Ota S; Kondo T; Kobayashi T; Kobayashi M; Asaka M; Imamura M
    Exp Hematol; 2007 Oct; 35(10):1562-6. PubMed ID: 17681668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
    Micklethwaite KP; Savoldo B; Hanley PJ; Leen AM; Demmler-Harrison GJ; Cooper LJ; Liu H; Gee AP; Shpall EJ; Rooney CM; Heslop HE; Brenner MK; Bollard CM; Dotti G
    Blood; 2010 Apr; 115(13):2695-703. PubMed ID: 20110422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.
    Wu QL; Liu XY; Nie DM; Zhu XX; Fang J; You Y; Zhong ZD; Xia LH; Hong M
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):477-484. PubMed ID: 26223913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood.
    Hanley PJ; Bollard CM; Brunstein CG
    Cytotherapy; 2015 Jun; 17(6):749-755. PubMed ID: 25632003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in umbilical cord blood cell therapy: the present and the future.
    Berglund S; Magalhaes I; Gaballa A; Vanherberghen B; Uhlin M
    Expert Opin Biol Ther; 2017 Jun; 17(6):691-699. PubMed ID: 28379044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The functional immaturity of dendritic cells can be relevant to increased tolerance associated with cord blood transplantation.
    Encabo A; Solves P; Carbonell-Uberos F; Miñana MD
    Transfusion; 2007 Feb; 47(2):272-9. PubMed ID: 17302774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
    D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
    Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation.
    Gao L; Zhang Y; Hu B; Liu J; Kong P; Lou S; Su Y; Yang T; Li H; Liu Y; Zhang C; Gao L; Zhu L; Wen Q; Wang P; Chen X; Zhong J; Zhang X
    J Clin Oncol; 2016 Aug; 34(24):2843-50. PubMed ID: 27400949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy for posttransplantation viral infections.
    Bollard CM; Kuehnle I; Leen A; Rooney CM; Heslop HE
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):143-55. PubMed ID: 14993880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant.
    Chiesa R; Gilmour K; Qasim W; Adams S; Worth AJ; Zhan H; Montiel-Equihua CA; Derniame S; Cale C; Rao K; Hiwarkar P; Hough R; Saudemont A; Fahrenkrog CS; Goulden N; Amrolia PJ; Veys P
    Br J Haematol; 2012 Mar; 156(5):656-66. PubMed ID: 22224700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.
    Stenger EO; Chiang KY; Haight A; Qayed M; Kean L; Horan J
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1845-52. PubMed ID: 26095669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives.
    Lo Presti V; Nierkens S; Boelens JJ; van Til NP
    Expert Rev Hematol; 2018 Mar; 11(3):209-218. PubMed ID: 29359983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation.
    Saliba RM; Rezvani K; Leen A; Jorgensen J; Shah N; Hosing C; Parmar S; Oran B; Olson A; Rondon G; Chen J; Martinez C; Hamdi A; Mehta RS; Chemaly RF; Saunders IM; Bollard CM; Shpall EJ
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1284-90. PubMed ID: 25708219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
    Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
    J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.